By Industry News
Toronto, Canada and Queensland, Australia – June 22, 2021 – MolecuLight Inc., the creator of a point-of-care fluorescence imaging device for detection of wounds containing elevated bacterial loads, announces it has signed LMT Surgical as its new Distributor in Australia and New Zealand. LMT, a provider of products and services to the medical market, will bring its comprehensive commercial capabilities to help meet the demand for the MolecuLight i:X to the wound care community in Australia and New Zealand.
“We are thrilled to be working with LMT Surgical to provide the support and training for the growing demand for our MolecuLight i:X point-of-care device in Australia and New Zealand,” says Anil Amlani, MolecuLight’s CEO. “We believe that LMT, with its impressive team and strong relationships with the leading clinicians and medical institutions, is the perfect partner for MolecuLight.”
“We are very excited to start collaborating with MolecuLight and promote the i:X system in Australia and New Zealand. The MolecuLight i:X device will complement our extensive wound care portfolio seamlessly,” says Daniel Jones, General Manager Sales & Marketing of LMT Surgical.
About MolecuLight, Inc.
MolecuLight is the manufacturer of MolecuLight i:X®, a real-time handheld fluorescence imaging device.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.